Melrose, MA, United States of America

Kevin Friedman

USPTO Granted Patents = 19 

 

 

Average Co-Inventor Count = 1.8

ph-index = 8

Forward Citations = 180(Granted Patents)


Location History:

  • Medford, MA (US) (2019 - 2020)
  • Melrose, MA (US) (2019 - 2024)

Company Filing History:


Years Active: 2019-2025

Loading Chart...
Loading Chart...
Loading Chart...
19 patents (USPTO):

Title: Kevin Friedman: Innovator in Adoptive Cell Therapies

Introduction

Kevin Friedman, based in Melrose, MA, is a notable inventor and innovator in the field of biotechnology, particularly in developing therapies that harness the power of the immune system. With a remarkable portfolio of 19 patents, Friedman has contributed significantly to advancements in adoptive cell therapies.

Latest Patents

Friedman's recent innovations include two notable patents. The first, titled "Methods for manufacturing adoptive cell therapies," outlines compositions and methods for manufacturing these therapies. It details techniques for harvesting populations of cells, isolating and activating peripheral blood mononuclear cells (PBMCs), expanding T cells, and effectively administering T cell therapeutics to individuals in need. The second patent, "Anti-BCMA CAR antibodies, conjugates, and methods of use," focuses on improved methods for detecting anti-BCMA CAR expression on T cells, showcasing his ongoing commitment to enhancing therapeutic strategies.

Career Highlights

Throughout his career, Friedman has gained valuable experience at leading biotechnology companies, including 2seventy Bio, Inc. and Bluebird Bio, Inc. His work at these organizations has positioned him as a pioneer in his field, further establishing his reputation as a leading inventor in the therapeutic landscape.

Collaborations

Kevin Friedman has collaborated with peers such as Richard Morgan and Molly Reed Perkins, contributing to a dynamic environment of innovation and excellence within his teams. These collaborations have not only enhanced his work but also pushed the boundaries of what is possible in cell therapy development.

Conclusion

Kevin Friedman's contributions to the field of biotechnology and his impressive portfolio of patents demonstrate his dedication to advancing medical treatments. His innovative methods and collaborative spirit continue to positively impact patient care and the future of adoptive cell therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…